INTRODUCTION: Causes of small-fiber peripheral neuropathies (SFN) are often undefined. In this study we investigated associations of serum autoantibodies, immunoglobulin G (IgG) vs fibroblast growth factor receptor-3 (FGFR-3), and immunoglobulin M (IgM) vs trisulfated heparan disaccharide (TS-HDS) in cryptogenic SFN. METHODS: One hundred fifty-five patients with biopsy-proven SFN and no identified cause for their neuropathy were blindly tested for serum IgM vs TS-HDS and IgG vs FGFR-3. RESULTS: Forty-eight percent of SFN patients had serum antibodies, 37% with IgM vs TS-HDS and 15% with IgG vs FGFR-3. TS-HDS antibodies were more frequent in SFN patients than in controls (P = .0012). Both antibodies were more common in females, and with non-length-dependent nerve pathology. Nintey-two percent of patients with acute-onset SFN had serum IgM vs TS-HDS. DISCUSSION: Autoantibodies directed against TS-HDS and FGFR-3 suggest an immune disorder in otherwise idiopathic SFN. Serum IgM vs TS-HDS may be a marker for SFN with an acute onset.
INTRODUCTION: Causes of small-fiber peripheral neuropathies (SFN) are often undefined. In this study we investigated associations of serum autoantibodies, immunoglobulin G (IgG) vs fibroblast growth factor receptor-3 (FGFR-3), and immunoglobulin M (IgM) vs trisulfated heparan disaccharide (TS-HDS) in cryptogenic SFN. METHODS: One hundred fifty-five patients with biopsy-proven SFN and no identified cause for their neuropathy were blindly tested for serum IgM vs TS-HDS and IgG vs FGFR-3. RESULTS: Forty-eight percent of SFNpatients had serum antibodies, 37% with IgM vs TS-HDS and 15% with IgG vs FGFR-3. TS-HDS antibodies were more frequent in SFNpatients than in controls (P = .0012). Both antibodies were more common in females, and with non-length-dependent nerve pathology. Nintey-two percent of patients with acute-onset SFN had serum IgM vs TS-HDS. DISCUSSION: Autoantibodies directed against TS-HDS and FGFR-3 suggest an immune disorder in otherwise idiopathic SFN. Serum IgM vs TS-HDS may be a marker for SFN with an acute onset.
Authors: Amanda C Y Chan; Hiu Yi Wong; Yao Feng Chong; Poh San Lai; Hock Luen Teoh; Alison Y Y Ng; Jennifer H M Hung; Yee Cheun Chan; Kay W P Ng; Joy Vijayan; Jonathan J Y Ong; Bharatendu Chandra; Chi Hsien Tan; Nurul H Rutt; Ti Myen Tan; Nur Hafiza Ismail; Einar Wilder-Smith; Herbert Schwarz; Hyungwon Choi; Vijay K Sharma; Anselm Mak Journal: Ann Neurol Date: 2021-12-01 Impact factor: 11.274
Authors: Peter Novak; Matthew P Giannetti; Emily Weller; Matthew J Hamilton; Shibani S Mukerji; Haitham S Alabsi; David Systrom; Sadie P Marciano; Donna Felsenstein; William J Mullally; David M Pilgrim; Mariana Castells Journal: Neurol Sci Date: 2022-09-28 Impact factor: 3.830
Authors: Margot Geerts; Bianca T A de Greef; Maurice Sopacua; Sander M J van Kuijk; Janneke G J Hoeijmakers; Catharina G Faber; Ingemar S J Merkies Journal: Neurology Date: 2021-03-25 Impact factor: 9.910
Authors: William J Mullally; David M Pilgrim; Peter Novak; Shibani S Mukerji; Haitham S Alabsi; David Systrom; Sadie P Marciano; Donna Felsenstein Journal: Ann Neurol Date: 2022-01-18 Impact factor: 11.274